The Lancet. Infectious diseases

Keyphrases

Publications

volume 24, number 9, 2024

You Li, Xin Wang
Unveiling the viral aetiologies of lower respiratory infections. The Lancet. Infectious diseases 24 (9) (2024)
Charles J Sande
The long-term efficacy of a respiratory syncytial virus vaccine for older adults. The Lancet. Infectious diseases 24 (9) (2024)
Nicole Bézay, Laura Wagner, Vera Kadlecek, Michaela Obersriebnig, Nina Wressnigg, Romana Hochreiter, Martina Schneider, Katrin Dubischar, Ulla Derhaschnig, Anton Klingler, Julian Larcher-Senn, Susanne Eder-Lingelbach, Wolfgang Bender
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies. The Lancet. Infectious diseases 24 (9) (2024)
Mirjam Groger, Michael Ramharter
Rapid diagnostic tests for Lassa fever: what do we aim for? The Lancet. Infectious diseases 24 (9) (2024)
Phrutsamon Wongnak, William H K Schilling, Podjanee Jittamala, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M Batty, Shivani Singh, Jindarat Kouhathong, Watcharee Pagornrat, Patpannee Khanthagan, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mayfong Mayxay, Kesinee Chotivanich, Mallika Imwong, Sasithon Pukrittayakamee, Elizabeth A Ashley, Arjen M Dondorp, Nicholas P J Day, Mauro M Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White, James A Watson, null null
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV). The Lancet. Infectious diseases 24 (9) (2024)
Leo G Visser
Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape. The Lancet. Infectious diseases 24 (9) (2024)
Jarel Elgin Tolentino, Spyros Lytras, Jumpei Ito, Edward C Holmes, Kei Sato
Recombination as an evolutionary driver of MERS-related coronavirus emergence. The Lancet. Infectious diseases 24 (9) (2024)
Guido Granata, Lone Simonsen, Nicola Petrosillo, Eskild Petersen
Mortality of H5N1 human infections might be due to H5N1 virus pneumonia and could decrease by switching receptor. The Lancet. Infectious diseases 24 (9) (2024)
Jelte Elsinga, Temmy Sunyoto, Letizia di Stefano, Pier Francesco Giorgetti, Htet Aung Kyi, Chiara Burzio, Ximena Campos Moreno, Chiedozie K Ojide, Nnennaya Ajayi, Richard Ewah, Emeka O Ogah, Chioma Dan-Nwafor, Anthony Ahumibe, Chinwe Lucia Ochu, Adebola Olayinka, Sylvie Jonckheere, Pascale Chaillet, Michel van Herp
Field evaluation of validity and feasibility of Pan-Lassa rapid diagnostic test for Lassa fever in Abakaliki, Nigeria: a prospective diagnostic accuracy study. The Lancet. Infectious diseases 24 (9) (2024)
Nobuko Arisue, Nirianne Marie Q Palacpac
Asymptomatic parasitemia and RTS,S vaccine efficacy. The Lancet. Infectious diseases 24 (9) (2024)
Muge Cevik, Lindsay C Thompson, Caryn Upton, Valéria Cavalcanti Rolla, Mookho Malahleha, Blandina Mmbaga, Nosipho Ngubane, Zamzurina Abu Bakar, Mohammed Rassool, Ebrahim Variava, Rodney Dawson, Suzanne Staples, Umesh Lalloo, Cheryl Louw, Francesca Conradie, Marika Eristavi, Anastasia Samoilova, Sergey N Skornyakov, Niyanda Elias Ntinginya, Frederick Haraka, George Praygod, Harriett Mayanja-Kizza, Janice Caoili, Vincent Balanag, Margareth Pretti Dalcolmo, Timothy McHugh, Robert Hunt, Priya Solanki, Anna Bateson, Angela M Crook, Stella Fabiane, Juliano Timm, Eugene Sun, Melvin Spigelman, Derek J Sloan, Stephen H Gillespie, null null
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. The Lancet. Infectious diseases 24 (9) (2024)
Philip J Rosenthal, Victor Asua, Jeffrey A Bailey, Melissa D Conrad, Deus S Ishengoma, Moses R Kamya, Charlotte Rasmussen, Fitsum G Tadesse, Aline Uwimana, David A Fidock
The emergence of artemisinin partial resistance in Africa: how do we respond? The Lancet. Infectious diseases 24 (9) (2024)
Ida Rask Moustsen-Helms, Peter Bager, Tine Graakjær Larsen, Frederik Trier Møller, Lasse Skafte Vestergaard, Morten Rasmussen, Christian Holm Hansen, null null
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study. The Lancet. Infectious diseases 24 (9) (2024)
Phrutsamon Wongnak, William H K Schilling, Podjanee Jittamala, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M Batty, Shivani Singh, Jindarat Kouhathong, Watcharee Pagornrat, Patpannee Khanthagan, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mayfong Mayxay, Kesinee Chotivanich, Mallika Imwong, Sasithon Pukrittayakamee, Elizabeth A Ashley, Arjen M Dondorp, Nicholas P J Day, Mauro M Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White, James A Watson, null null
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV). The Lancet. Infectious diseases 24 (9) (2024)
Jelte Elsinga, Temmy Sunyoto, Letizia di Stefano, Pier Francesco Giorgetti, Htet Aung Kyi, Chiara Burzio, Ximena Campos Moreno, Chiedozie K Ojide, Nnennaya Ajayi, Richard Ewah, Emeka O Ogah, Chioma Dan-Nwafor, Anthony Ahumibe, Chinwe Lucia Ochu, Adebola Olayinka, Sylvie Jonckheere, Pascale Chaillet, Michel van Herp
Field evaluation of validity and feasibility of Pan-Lassa rapid diagnostic test for Lassa fever in Abakaliki, Nigeria: a prospective diagnostic accuracy study. The Lancet. Infectious diseases 24 (9) (2024)
null The Lancet Infectious Diseases
Oropouche fever, the mysterious threat. The Lancet. Infectious diseases 24 (9) (2024)
Sebastiaan J van Hal, Norelle Sherry, Geoff Coombs, Shakeel Mowlaboccus, David M Whiley, Monica M Lahra
Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone. The Lancet. Infectious diseases 24 (9) (2024)
Peter J White, Trystan Leng, Dariya Nikitin, Lilith K Whittles
The potential role of the 4CMenB vaccine in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial. The Lancet. Infectious diseases 24 (9) (2024)
Philip J Rosenthal, Victor Asua, Jeffrey A Bailey, Melissa D Conrad, Deus S Ishengoma, Moses R Kamya, Charlotte Rasmussen, Fitsum G Tadesse, Aline Uwimana, David A Fidock
The emergence of artemisinin partial resistance in Africa: how do we respond? The Lancet. Infectious diseases 24 (9) (2024)
Mirjam Groger, Michael Ramharter
Rapid diagnostic tests for Lassa fever: what do we aim for? The Lancet. Infectious diseases 24 (9) (2024)
Muge Cevik, Lindsay C Thompson, Caryn Upton, Valéria Cavalcanti Rolla, Mookho Malahleha, Blandina Mmbaga, Nosipho Ngubane, Zamzurina Abu Bakar, Mohammed Rassool, Ebrahim Variava, Rodney Dawson, Suzanne Staples, Umesh Lalloo, Cheryl Louw, Francesca Conradie, Marika Eristavi, Anastasia Samoilova, Sergey N Skornyakov, Niyanda Elias Ntinginya, Frederick Haraka, George Praygod, Harriett Mayanja-Kizza, Janice Caoili, Vincent Balanag, Margareth Pretti Dalcolmo, Timothy McHugh, Robert Hunt, Priya Solanki, Anna Bateson, Angela M Crook, Stella Fabiane, Juliano Timm, Eugene Sun, Melvin Spigelman, Derek J Sloan, Stephen H Gillespie, null null
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. The Lancet. Infectious diseases 24 (9) (2024)
Michal Juraska, Angela M Early, Li Li, Stephen F Schaffner, Marc Lievens, Akanksha Khorgade, Brian Simpkins, Nima S Hejazi, David Benkeser, Qi Wang, Laina D Mercer, Samuel Adjei, Tsiri Agbenyega, Scott Anderson, Daniel Ansong, Dennis K Bii, Patrick B Y Buabeng, Sean English, Nicholas Fitzgerald, Jonna Grimsby, Simon K Kariuki, Kephas Otieno, François Roman, Aaron M Samuels, Nelli Westercamp, Christian F Ockenhouse, Opokua Ofori-Anyinam, Cynthia K Lee, Bronwyn L MacInnis, Dyann F Wirth, Peter B Gilbert, Daniel E Neafsey
Genotypic analysis of RTS,S/AS01 E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. The Lancet. Infectious diseases 24 (9) (2024)
Guofang Deng, Liang Fu
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis. The Lancet. Infectious diseases 24 (9) (2024)
You Li, Xin Wang
Unveiling the viral aetiologies of lower respiratory infections. The Lancet. Infectious diseases 24 (9) (2024)
null null
Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. The Lancet. Infectious diseases 24 (9) (2024)
Guofang Deng, Liang Fu
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis. The Lancet. Infectious diseases 24 (9) (2024)
Shamez N Ladhani, Peter J White, Helen Campbell, Sema Mandal, Ray Borrow, Nick Andrews, Sunil Bhopal, John Saunders, Hamish Mohammed, Lana Drisdale-Gordon, Emma Callan, Katy Sinka, Kate Folkard, Helen Fifer, Mary E Ramsay
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK. The Lancet. Infectious diseases 24 (9) (2024)
Ann R Falsey, Tessa Hosman, Arangassery Rosemary Bastian, Sjouke Vandenberghe, Eric K H Chan, Macaya Douoguih, Esther Heijnen, Christy A Comeaux, Benoit Callendret, null null
Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study. The Lancet. Infectious diseases 24 (9) (2024)
Malin Inghammar, Fredrik Kahn
Immune evasiveness of SARS-CoV-2 variants and vaccine selection. The Lancet. Infectious diseases 24 (9) (2024)
Charles J Sande
The long-term efficacy of a respiratory syncytial virus vaccine for older adults. The Lancet. Infectious diseases 24 (9) (2024)
Michal Juraska, Angela M Early, Li Li, Stephen F Schaffner, Marc Lievens, Akanksha Khorgade, Brian Simpkins, Nima S Hejazi, David Benkeser, Qi Wang, Laina D Mercer, Samuel Adjei, Tsiri Agbenyega, Scott Anderson, Daniel Ansong, Dennis K Bii, Patrick B Y Buabeng, Sean English, Nicholas Fitzgerald, Jonna Grimsby, Simon K Kariuki, Kephas Otieno, François Roman, Aaron M Samuels, Nelli Westercamp, Christian F Ockenhouse, Opokua Ofori-Anyinam, Cynthia K Lee, Bronwyn L MacInnis, Dyann F Wirth, Peter B Gilbert, Daniel E Neafsey
Genotypic analysis of RTS,S/AS01 E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. The Lancet. Infectious diseases 24 (9) (2024)
Nobuko Arisue, Nirianne Marie Q Palacpac
Asymptomatic parasitemia and RTS,S vaccine efficacy. The Lancet. Infectious diseases 24 (9) (2024)
null null
Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. The Lancet. Infectious diseases 24 (9) (2024)
Nicole Bézay, Laura Wagner, Vera Kadlecek, Michaela Obersriebnig, Nina Wressnigg, Romana Hochreiter, Martina Schneider, Katrin Dubischar, Ulla Derhaschnig, Anton Klingler, Julian Larcher-Senn, Susanne Eder-Lingelbach, Wolfgang Bender
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies. The Lancet. Infectious diseases 24 (9) (2024)
Jennifer Cohn, Marc Mendelson, Souha S Kanj, Nusrat Shafiq, Icaro Boszczowski, Ramanan Laxminarayan
Accelerating antibiotic access and stewardship: a new model to safeguard public health. The Lancet. Infectious diseases 24 (9) (2024)
Shamez N Ladhani, Peter J White, Helen Campbell, Sema Mandal, Ray Borrow, Nick Andrews, Sunil Bhopal, John Saunders, Hamish Mohammed, Lana Drisdale-Gordon, Emma Callan, Katy Sinka, Kate Folkard, Helen Fifer, Mary E Ramsay
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK. The Lancet. Infectious diseases 24 (9) (2024)
Bipin Adhikari, Lorenz Von Seidlein
Anthony Fauci: a life on page. The Lancet. Infectious diseases 24 (9) (2024)
Kogieleum Naidoo, Rubeshan Perumal, Helen Cox, Barun Mathema, Marian Loveday, Nazir Ismail, Shaheed Vally Omar, Sophia B Georghiou, Amrita Daftary, Max O'Donnell, Norbert Ndjeka
The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience. The Lancet. Infectious diseases 24 (9) (2024)
Anders Björkman, Pedro Gil, Michael Alifrangis
Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug. The Lancet. Infectious diseases 24 (9) (2024)
Collins Kipngetich Tanui, Nicaise Ndembi, Yenew Kebede, Sofonias Kifle Tessema
Artificial intelligence to transform public health in Africa. The Lancet. Infectious diseases 24 (9) (2024)
Raymond J Dattwyler, Paul M Arnaboldi
Vaccination hesistancy in Lyme borreliosis. The Lancet. Infectious diseases 24 (9) (2024)
Raymond J Dattwyler, Paul M Arnaboldi
Vaccination hesistancy in Lyme borreliosis. The Lancet. Infectious diseases 24 (9) (2024)
Malin Inghammar, Fredrik Kahn
Immune evasiveness of SARS-CoV-2 variants and vaccine selection. The Lancet. Infectious diseases 24 (9) (2024)
Ida Rask Moustsen-Helms, Peter Bager, Tine Graakjær Larsen, Frederik Trier Møller, Lasse Skafte Vestergaard, Morten Rasmussen, Christian Holm Hansen, null null
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study. The Lancet. Infectious diseases 24 (9) (2024)
Collins Kipngetich Tanui, Nicaise Ndembi, Yenew Kebede, Sofonias Kifle Tessema
Artificial intelligence to transform public health in Africa. The Lancet. Infectious diseases 24 (9) (2024)
Peter J White, Trystan Leng, Dariya Nikitin, Lilith K Whittles
The potential role of the 4CMenB vaccine in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial. The Lancet. Infectious diseases 24 (9) (2024)
Ann R Falsey, Tessa Hosman, Arangassery Rosemary Bastian, Sjouke Vandenberghe, Eric K H Chan, Macaya Douoguih, Esther Heijnen, Christy A Comeaux, Benoit Callendret, null null
Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study. The Lancet. Infectious diseases 24 (9) (2024)
Leo G Visser
Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape. The Lancet. Infectious diseases 24 (9) (2024)
Kogieleum Naidoo, Rubeshan Perumal, Helen Cox, Barun Mathema, Marian Loveday, Nazir Ismail, Shaheed Vally Omar, Sophia B Georghiou, Amrita Daftary, Max O'Donnell, Norbert Ndjeka
The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience. The Lancet. Infectious diseases 24 (9) (2024)
Jennifer Cohn, Marc Mendelson, Souha S Kanj, Nusrat Shafiq, Icaro Boszczowski, Ramanan Laxminarayan
Accelerating antibiotic access and stewardship: a new model to safeguard public health. The Lancet. Infectious diseases 24 (9) (2024)